Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Igrelimogene litadenorepvec - TILT Biotherapeutics

Next Previous
X
Search
Drug Profile

Igrelimogene litadenorepvec - TILT Biotherapeutics

Alternative Names: Ad5/3-E2F-d24-hTNFa-IRES-hIL2; TILT 123

Latest Information Update: 12 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TILT Biotherapeutics
  • Developer MSD BV; TILT Biotherapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 2 expression stimulants; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 09 Sep 2024 Efficacy and adverse events data from the TUNIMO phase I trial in Solid tumours released by TILT Biotherapeutics
  • 31 May 2024 Updated efficacy and adverse events data from a phase I trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 May 2024 Updated efficacy and adverse events data from a phase I trial in Ovarian cancer released by TILT Biotherapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top